CarlMagnus Hogerkorp - Cyxone AB COO CEO
| CYXO Stock | SEK 0.03 0.01 21.57% |
Insider
CarlMagnus Hogerkorp is COO CEO of Cyxone AB
| Age | 53 |
| Phone | 46 7 08 88 21 72 |
| Web | https://www.cyxone.com |
Cyxone AB Management Efficiency
The company has return on total asset (ROA) of (0.5861) % which means that it has lost $0.5861 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (1.0658) %, meaning that it generated substantial loss on money invested by shareholders. Cyxone AB's management efficiency ratios could be used to measure how well Cyxone AB manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Martin mark | Xbrane Biopharma AB | 43 | |
| Sren MSc | Hansa Biopharma AB | 58 | |
| Pr Gellerfors | BioArctic AB | 76 | |
| Erik Domines | Xbrane Biopharma AB | 59 | |
| Emanuel Bjrne | Hansa Biopharma AB | 50 | |
| Harald Borgeke | BioArctic AB | N/A | |
| Nina Ivers | Xbrane Biopharma AB | 53 | |
| Gunilla Osswald | BioArctic AB | 62 | |
| David Vikstrm | Xbrane Biopharma AB | 46 | |
| Pr Lannfelt | BioArctic AB | 74 | |
| Samuel Wagner | Xbrane Biopharma AB | N/A | |
| Anne Lanner | Hansa Biopharma AB | 54 | |
| Klaus Sindahl | Hansa Biopharma AB | N/A | |
| Christer Mller | BioArctic AB | 64 | |
| Associate Gier | Xbrane Biopharma AB | N/A | |
| Oskar Bosson | BioArctic AB | 47 | |
| Maria Edebrink | Xbrane Biopharma AB | 54 | |
| Johanna Flting | BioArctic AB | 51 | |
| Katja Margell | Hansa Biopharma AB | N/A | |
| Anette Lindqvist | Xbrane Biopharma AB | 57 | |
| Jan Mattsson | BioArctic AB | 63 | |
Management Performance
| Return On Equity | -1.07 | |||
| Return On Asset | -0.59 |
Cyxone AB Leadership Team
Elected by the shareholders, the Cyxone AB's board of directors comprises two types of representatives: Cyxone AB inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Cyxone. The board's role is to monitor Cyxone AB's management team and ensure that shareholders' interests are well served. Cyxone AB's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Cyxone AB's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Malin Berthold, Project Manager | ||
| Theresa Olsen, Director | ||
| Bert Junno, Chairman of the Board | ||
| Ola Skanung, Interim Chief Executive Officer, Chief Financial Officer | ||
| Mikael Lindstam, Chief Operating Officer, Director | ||
| Erika Samuelsson, Chief Officer | ||
| Saad Gilani, Director | ||
| CarlMagnus Hogerkorp, COO CEO |
Cyxone Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Cyxone AB a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.07 | |||
| Return On Asset | -0.59 | |||
| Current Valuation | 7.74 M | |||
| Shares Outstanding | 98.44 M | |||
| Shares Owned By Insiders | 25.38 % | |||
| Price To Book | 1.00 X | |||
| Price To Sales | 5,168 X | |||
| EBITDA | (43.23 M) | |||
| Net Income | (45.03 M) | |||
| Cash And Equivalents | 56.34 M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Cyxone Stock Analysis
When running Cyxone AB's price analysis, check to measure Cyxone AB's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cyxone AB is operating at the current time. Most of Cyxone AB's value examination focuses on studying past and present price action to predict the probability of Cyxone AB's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cyxone AB's price. Additionally, you may evaluate how the addition of Cyxone AB to your portfolios can decrease your overall portfolio volatility.